Trials / Completed
CompletedNCT01852682
A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Kissei Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to investigate efficacy and safety, when administering PA21, in peritoneal dialysis patients having hyperphosphatemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PA21 |
Timeline
- Primary completion
- 2014-03-01
- First posted
- 2013-05-14
- Last updated
- 2014-11-13
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01852682. Inclusion in this directory is not an endorsement.